<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Clinical observations suggest that patients with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) may benefit from treatment with <z:chebi fb="0" ids="37733">cholinesterase inhibitors</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>This study evaluated the efficacy and safety of <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> for relieving symptoms of <z:hpo ids='HP_0000726'>dementia</z:hpo> in VaD </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Patients (n=603; mean age, 73.9 years; 55.2% men) with probable (70.5%) or possible (29.5%) VaD, according to criteria of the National Institute of <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">Neurological Disorders</z:e> and <z:hpo ids='HP_0001297'>Stroke</z:hpo> (NINDS) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN), were randomized to 24 weeks of treatment with <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> 5 mg/d (n=198), <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> 10 mg/d (5 mg/d for first 28 days; n=206), or placebo (n=199) </plain></SENT>
<SENT sid="3" pm="."><plain>Analyses were based on the intent-to-treat population </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: At week 24, both <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> groups showed significant improvement in cognition versus placebo on the <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's Disease</z:e> Assessment Scale-cognitive subscale (mean change from baseline score effect size: <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> 5 mg/d, -1.90; P=0.001; <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> 10 mg/d, -2.33; P&lt;0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Significant improvements in patients' global function were seen versus placebo at week 24 (observed cases), on the Clinician's Interview-Based Impression of Change-Plus version only for patients on <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> 5 mg/d (P=0.014), and on the Sum of the Boxes of the Clinical <z:hpo ids='HP_0000726'>Dementia</z:hpo> Rating only for patients on 10 mg/d (P=0.007) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="53289,53290,53292">Donepezil</z:chebi>-treated patients showed significant benefits in activities of daily living over placebo on the <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's Disease</z:e> Functional Assessment and Change Scale (mean change from baseline score effect size at week 24: <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> 5 mg/d, -1.31, P=0.02; <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> 10 mg/d, -1.31, P=0.02) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="53289,53290,53292">Donepezil</z:chebi> was well tolerated </plain></SENT>
<SENT sid="8" pm="."><plain>Withdrawal rates due to adverse events were relatively low (placebo, 11.1%; <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> 5 mg/d, 11.1%; <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> 10 mg/d, 21.8%; P=0.005 versus placebo) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These data demonstrate that <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition </plain></SENT>
</text></document>